Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who fully understand the study, choose to take part voluntarily, and sign a consent form
• People aged 18 to 80 years old
• People who have been diagnosed with pancreatic cancer that cannot be surgically removed or has spread to other parts of the body, confirmed by a tissue sample (biopsy)
• People whose cancer has been shown on scans to have continued growing after receiving two previous standard lines of treatment
• People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines
• People who are reasonably well and able to carry out daily activities, as rated on a standard scale (ECOG score of 0–2; confirm with trial site)
• People whose doctors estimate they are likely to live for at least 2 more months
• People whose blood test results show their white blood cells, platelets, and red blood cells are within acceptable levels, without having needed a blood transfusion or blood-boosting treatments in the 14 days before testing
• People whose liver and kidney function blood test results fall within acceptable ranges for this trial (confirm with trial site for exact values)
• Women who could become pregnant must have a negative pregnancy blood test within 7 days before joining, and must agree to use appropriate contraception during the trial and for 6 months after the last dose of the trial drug

Who may not be able to join:

• People who have had a serious allergic reaction to any of the trial drugs or their ingredients
• People with serious, uncontrolled infections or other serious uncontrolled health conditions, or moderate to severe kidney damage (for example, uncontrolled high blood pressure or diabetes)
• People with certain heart conditions, including specific abnormal heart rhythms, significant blockages in the heart's electrical system, poor heart pumping function (below 50%), a history of heart attack or unstable chest pain within the past 6 months, or other serious heart-related issues (confirm with trial site for full details)
• People with an active hepatitis B or hepatitis C infection showing high levels of the virus in their blood (people who carry the virus without active disease may not be excluded — confirm with trial site)
• People who are HIV positive
• People whose scans show a blocked bowel
• People who currently have, or have previously had, another type of cancer — with some exceptions for certain skin cancers, some cancers that have been in early stages and well controlled, or other cancers that have been successfully treated and have not required treatment in the past five years (confirm with trial site)
• Women who are pregnant or breastfeeding, or people of reproductive age who are unwilling to use contraception
• People who currently need treatment for another cancer at the same time
• People who have experienced significant coughing up of blood (at least 2.5 mL of bright red blood) in the month before the first dose
• People who have experienced a blocked artery, serious bleeding (not related to surgery), or signs of a high risk of serious bleeding in the 6 months before the first dose
• People who have brain or spinal cord metastases causing symptoms, or who have cancer affecting the membranes around the brain or causing spinal cord compression
• People who have taken part in another clinical trial and received an experimental drug within one month before the first dose
• People whom the trial doctors consider unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.